Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 25, 2025
Event: Filing of a prospectus supplement to Registration Statement on Form S-3 (No. 333-279588) to sell common stock under an equity distribution agreement with A.G.P. / Alliance Global Partners.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on capital structure and equity distribution details.
| Metric | Value |
|---|---|
| Total Shares Authorized for Sale (Prospectus Supplement) | $5,239,073 |
| Shares Sold in Prior 12 Months | $1,546,338 |
| Remaining Shares Available for Sale | $3,692,735 |
Material Changes
The filing reports the activation of a specific equity distribution capacity. The Company has updated its registration statement to permit the sale of up to $5,239,073 of common stock. This represents a continuation of an existing "at-the-market" offering program rather than a discrete change in operational performance.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, operational outlook, or management commentary regarding business strategy or clinical progress.
Risks and Contingencies: The document includes a standard disclaimer stating that the report does not constitute an offer to sell or a solicitation of an offer to buy shares in any state where such offer would be unlawful prior to registration or qualification under local securities laws.
Investor Verification Checklist
- Verify the current market price of PCSA to calculate the actual number of shares represented by the $5,239,073 authorization.
- Review the full Form S-3 Registration Statement (No. 333-279588) for the complete terms of the equity distribution agreement with A.G.P. / Alliance Global Partners.
- Check recent trading volume to assess the potential dilution impact of the $3,692,735 remaining available for sale.
- Confirm if the $1,546,338 sold in the prior 12 months aligns with the Company's stated capital raise goals in previous filings.